, a journal of the American Association for Cancer Research.
‘p38MAPK inhibitors and a MK2 inhibitors could block different parts of the same pathway leading to bone loss. So, they could benefit patients taking chemotherapy, who are at high risk of bone loss.’
The researchers further found that this process occurs in males and females and is independent of cancer type.
Bone loss can lead to osteoporosis and fractures is a major problem for cancer patients who receive chemotherapy and radiation.
Since the hormone estrogen plays an important role in maintaining bone health, bone loss is especially pronounced among postmenopausal women with breast cancer who are treated using therapies aimed at eliminating estrogen.
Men and children treated for other cancers also experience bone loss, suggesting that eliminating estrogen is not the only trigger leading to bone degeneration.
“Researchers have understood that this bone loss has to be due to more than just hormone loss,” said senior author Sheila A. Stewart, PhD, a professor of cell biology & physiology. “Cancer patients who receive chemotherapy and radiation lose a lot more bone than women with breast can Read More
Leave a Replay
Hello!! How are you? I spent some time over the last 2 weeks really thinking about my New Year’s Resolutions and Goals for 2020. Related Articles 2020 Goals – New Everything
ADVERTISEMENTHello!! How are you? I spent some time over the last 2 weeks really thinking about my New Year’s Resolutions and Goals for 2020. Related Articles 2020 Goals – New Everything